| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 10mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
BMS-955176 targets the HIV-1 Gag polyprotein, specifically the capsid (CA) region, inhibiting the protease-mediated cleavage of the CA-SP1 junction. This blocks the final step of viral maturation, preventing the formation of infectious viral particles. It is a second-generation maturation inhibitor with improved potency and resistance profile.
|
|---|---|
| ln Vitro |
GSK3532795 has a Kd of 3.2 ± 0.6, 4.3 ± 2.0, 6.5 ± 2.2, and 33.6 ± 5.9 nM against HIV WT, HIV V362I, HIV V370A, and HIV ΔV370, respectively [1].
BMS-955176 is a potent HIV-1 maturation inhibitor with EC50 values of 1.9 nM, 10.2 nM (in human serum), 2.7 nM, and 13 nM for HIV-1 WT, HIV-1 WT (human serum), HIV-1 V370A, and HIV-1 ΔV370, respectively. The compound is orally active. |
| ln Vivo |
BMS-955176 is orally active and has been evaluated in clinical trials for the treatment of HIV-1 infection. As a second-generation maturation inhibitor, it shows activity against HIV-1 strains resistant to first-generation maturation inhibitors. Specific animal model data are not extensively detailed in standard reference sources.
|
| Enzyme Assay |
The antiviral activity of BMS-955176 can be assessed using in vitro cell-based antiviral assays. HIV-1-infected cells are treated with increasing concentrations of BMS-955176, and viral replication is measured by quantifying viral p24 antigen or by using a reporter gene assay. EC50 values are determined from dose-response curves.
|
| Cell Assay |
The antiviral activity of BMS-955176 is evaluated in vitro using HIV-1-infected cell lines such as MT-4 cells or primary human peripheral blood mononuclear cells (PBMCs). Cells are infected with HIV-1 at a defined multiplicity of infection and treated with increasing concentrations of BMS-955176. Viral replication is assessed by measuring p24 antigen production or by using a luciferase reporter assay.
|
| Animal Protocol |
BMS-955176 is administered orally in preclinical and clinical studies. In animal models, the compound would be evaluated for its pharmacokinetic properties and antiviral efficacy. Specific in vivo animal experimental protocols are not extensively detailed in standard reference sources.
|
| ADME/Pharmacokinetics |
BMS-955176 is orally active. It has a molecular formula of C36H53N3O7 and a molecular weight of 639.82. Its UNII code is 4CA9IAU7RJ. Specific pharmacokinetic parameters such as half-life, bioavailability, and plasma protein binding are not extensively detailed in standard reference sources.
|
| Toxicity/Toxicokinetics |
The toxicity profile of BMS-955176 is not extensively documented in standard reference sources. As an HIV-1 maturation inhibitor, it is generally well-tolerated. Specific LD50 values and organ-specific toxicity data are not readily available.
|
| References | |
| Additional Infomation |
BMS-955176 is being investigated in the clinical trial NCT02415595 (a dose-exploration study of BMS-955176 for the treatment of HIV-1 infection in untreated adults).
BMS-955176 (CAS# 1392312-45-6) is also known as GSK3532795. It is a potent, orally active, second-generation HIV-1 maturation inhibitor. BMS-955176 has been evaluated in clinical trials for the treatment of HIV-1 infection. It shows activity against HIV-1 strains resistant to first-generation maturation inhibitors. |
| Molecular Formula |
C42H62N2O4S
|
|---|---|
| Molecular Weight |
691.0177
|
| Exact Mass |
690.44
|
| Elemental Analysis |
C, 73.00; H, 9.04; N, 4.05; O, 9.26; S, 4.64
|
| CAS # |
1392312-45-6
|
| Related CAS # |
1392312-45-6;2023808-13-9 (HCl);2023798-97-0 (HCl hydrate);2097784-79-5 (oxalate); 2097784-79-5 (TFA);
|
| PubChem CID |
60152109
|
| Appearance |
White to off-white solid powder
|
| LogP |
6.5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
49
|
| Complexity |
1440
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@H]4[C@]([C@@]3(CC2)C)(CC[C@@H]5[C@@]4(CC=C(C5(C)C)C6=CC=C(C=C6)C(=O)O)C)C)NCCN7CCS(=O)(=O)CC7
|
| InChi Key |
XDMUFNNPLXHNKA-ZTESCHFWSA-N
|
| InChi Code |
InChI=1S/C42H62N2O4S/c1-28(2)31-14-19-42(43-22-23-44-24-26-49(47,48)27-25-44)21-20-40(6)33(36(31)42)12-13-35-39(5)17-15-32(29-8-10-30(11-9-29)37(45)46)38(3,4)34(39)16-18-41(35,40)7/h8-11,15,31,33-36,43H,1,12-14,16-27H2,2-7H3,(H,45,46)/t31-,33+,34-,35+,36+,39-,40+,41+,42-/m0/s1
|
| Chemical Name |
4‑((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)‑3a-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13boctadecahydro‑1H‑cyclopenta[a]chrysen-9-yl)benzoic
Acid
|
| Synonyms |
GSK3532795 GSK-3532795 GSK 3532795 BMS-955176 BMS 955176 BMS955176.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4471 mL | 7.2357 mL | 14.4714 mL | |
| 5 mM | 0.2894 mL | 1.4471 mL | 2.8943 mL | |
| 10 mM | 0.1447 mL | 0.7236 mL | 1.4471 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA